MŞMurat Şahin

Murat Şahin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Murat Şahin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Alper Guzeltas

    Department of Pediatric Cardiology, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, University of Health Sciences, Istanbul 34303, Turkey

    5 shared publications
  • Selman Gokalp

    Department of Pediatric Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, University of Health Sciences, Istanbul 34303, Türkiye

    4 shared publications
  • Sezen Ugan Atik

    Department of Pediatric Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul

    4 shared publications
  • Ensar Duras

    Department of Pediatric Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Türkiye

    3 shared publications
  • Erman Cilsal

    Department of Pediatric Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Türkiye

    3 shared publications
  • Eser Sendesen

    Department of Audiology Hacettepe University Ankara Turkey

    2 shared publications

Latest Publications

  • Early‐Term Outcomes of Percutanous Pulmonary Valve Implantation With the Meril's Myval Pulmonary Valve—Single Center Experience From Turkey

    by Alper Guzeltas, Ensar Duras, Recep Siyar Balik, Erman Cilsal, Sezen Ugan Atik, Murat Sahin, Selman Gokalp

    Background: Recurrent interventions are required following surgical treatment of congenital heart diseases involving pathologies of the right ventricular outflow tract (RVOT). Percutaneous pulmonary valve implantation (PPVI) is one of the most commonly employed catheter‐based interventions for this purpose. Aims: The aim of this study is to share the early‐term feasibility, effectiveness, and hemodynamic outcomes of PPVI using Meril's Myval pulmonary valve in the largest patient series from a single center. Methods: This study included patients with congenital heart disease who had RVOT dysfunction following surgical repair or balloon valvuloplasty (e.g., after pulmonary stenosis intervention). Among the 132 patients planned for PPVI with the Meril's Myval between January 2021 and February 2024, five were excluded due to coronary compression risk identified during balloon sizing. The procedure was initiated in the remaining 127 patients. In three of these cases, the procedure could not be completed due to intra‐procedural complications (stent embolization in two patients and valve embolization in one). As a result, a total of 124 patients (97.6%) underwent successful PPVI. Hemodynamic data before and after the procedure and early follow‐up outcomes were recorded. Results: Seventy‐three patients (59%) were male, with a median age of 16.1 years (range 5.0 to 68.6 years) and a median weight of 52 kg (range 17–112 kg). The most common underlying diagnosis was tetralogy of Fallot ( n = 91, 73%), and 82 patients (66%) had a native RVOT or transannular patch repair. PPVI was performed for predominantly regurgitant lesions in 73 patients (59%), predominantly stenotic lesions in 27 (22%), and mixed lesions in 24 (19%). Bioprosthetic valve dysfunction was present in 12 patients (10%) and homograft/conduit dysfunction in 30 patients (24%). The median interval between the last cardiac surgery and PPVI was 12.3 years (range 1.1–36.2 years). A hybrid approach with lateral thoracotomy was required in three patients due to unfavorable venous access or anatomy. Pre‐stenting was performed in 114 cases (92%), of which 12 were conducted in separate sessions. The median valve size was 27.5 mm (range 20–32 mm), and valves ≥ 29 mm were implanted in 60 cases (48%). In all cases, the largest feasible valve was selected to facilitate future interventions. Following implantation, a significant reduction was observed in systolic right ventricular pressure (RVP) (from 41.9 ± 23.5 to 29.1 ± 8.9 mmHg, p < 0.001) and RVOT gradient (from 20.9 ± 23.8 to 7.6 ± 5.5 mmHg, p < 0.001). The median hospital stay was 3 days (range 1–9 days). Over a median follow‐up period of 1.6 years (range 0.3–3.6 years), no endocarditis, stent fractures, or deaths were reported. A total of 122 patients (98%) had none or only mild pulmonary regurgitation during follow‐up. An additional patient developed valve regurgitation approximately 1.5 years after the procedure, and a reintervention is being considered. Conclusions: The initial experience with the Meril's Myval valve in the pulmonary position demonstrates excellent safety and procedural success. Its favorable profile, particularly in patients with prior prosthetic material or significantly dilated RVOTs, highlights its potential as a reliable and preferred alternative with minimal complication rates.

  • Recanalisation and confluent reconstruction of pulmonary arteries in patients with left pulmonary artery disconnection

    by Mustafa Nalbant, Murat Şahin, Selman Gökalp, Sezen Ugan Atik, Sertaç Haydin, Alper Güzeltaş

    Unilateral absence of the pulmonary artery is a rare congenital defect requiring advanced imaging for diagnosis. We present two cases with a connection between a patent ductus arteriosus remnant and the left pulmonary artery. Therapeutic approaches, including imaging findings and management strategies, are discussed to highlight diagnostic and treatment considerations.

  • Open Access

    Transcatheter fenestration in Fontan failure: Our clinical experience

    by Ensar Duras, Recep Siyar Balik, Perver Arslan, Erman Cilsal, Murat Sahin, Ibrahim Cansaran Tanidir, Yakup Ergul, Alper Guzeltas

    Background: The aim of our study was to evaluate the hemodynamic effects and clinical outcomes of transcatheter fenestration in patients who developed Fontan failure. Methods: Between January 2014 and December 2022, among a total of 187 patients undergoing the Fontan operation, 10 (6 males, 4 females; median age: 10.9 years; range, 4.2 to 23 years) who underwent transcatheter creation or dilation of a Fontan fenestration due to the development of Fontan failure were retrospectively analyzed. Demographic data, laboratory results, echocardiographic findings, and catheterization parameters of the patients were recorded. The patients were classified into two groups based on the timing of Fontan failure: those who underwent fenestration before hospital discharge constituted the early-stage group, while those who underwent fenestration after discharge were assigned to the late-stage group. These two groups were compared in terms of hemodynamic parameters, changes in oxygen saturation, and complication rates. Results: Transcatheter fenestration was performed in five patients due to Fontan failure in the early postoperative period, and in five patients in the late period. The median follow-up duration was 2.2 (range, 0.1 to 6) years. Following the procedure, pleural effusion regressed in four patients; median systemic venous pressure decreased by 3.4 (range, 2 to 9) mmHg, while median oxygen saturation dropped by 5.9% (range, 3 to 9%). Clinical improvement was observed in 70% of the patients within the first month. However, one patient died on postoperative Day 44 due to low cardiac output. Fenestration was performed in three patients with protein-losing enteropathy, and clinical improvement was achieved in all of them. Conclusion: Transcatheter Fontan fenestration is a reliable therapeutic option for reducing systemic venous pressure and achieving hemodynamic improvement in symptomatic Fontan patients. Our study highlights the low complication rates and the potential of this procedure to yield favorable clinical outcomes. Transcatheter fenestration plays an important role in the management of high-risk Fontan patients.

  • Open Access

    Early-term results of percutaneous pulmonary valve implantation (valve-in-valve) in dysfunctional bioprosthetic valves in pulmonary position

    by Ensar Duras, Erman Çilsal, Selman Gökalp, Sezen Ugan Atik, Murat Şahin, Bekir Yükcü, Alper Güzeltaş

    Background: This study aimed to assess the outcomes of valve-in-valve implantation within previously placed bioprosthetic valves. Methods: This single-center retrospective study included patients who underwent percutaneous valve-in-valve procedures between July 2014 and September 2023. These patients had previously received pulmonary bioprosthetic valves via surgical or transcatheter methods. Results: The study included 20 patients (13 males, 7 females; mean age: 20.4±7.1 years; range, 10.8 to 35.8 years). Preprocedural assessment revealed stenotic dysfunction in 12 patients, regurgitant dysfunction in two patients, and a combination of both in six patients. Following implantation, there was a notable improvement in invasive measurements; systolic right ventricular pressure decreased from 64.0±24.5 mmHg to 31.3±6.7 mmHg (p Conclusion: Valve-in-valve implantation within previously placed bioprosthetic valves is a feasible and safe approach, offering symptom relief and eliminating the need for further surgical interventions.

  • Predictors of prolonged pleural effusion after Fontan operation

    by Betül Çınar, Sezen Ugan Atik, Selman Gökalp, Erman Çilsal, Murat Şahin, Hacer Kamalı, İsMihan Selen Onan, Serhat Bahadır Genç, Okan Yıldız, Sertaç Haydin, et al.

    Prolonged pleural effusion is a fairly common condition which has considerable impact on complicated and longer hospital stays after Fontan surgery. Identifying the patient population prone to have pleural effusions is still seeking for an answer. This study is to determine the variables that may predict prolonged pleural effusion according to the data of 69 patients who underwent Fontan operation between June 2018 and December 2020 and survived to date. Prolonged pleural effusion was defined as the need for a chest tube for more than 7 days. Two patient groups, with and without prolonged effusion, were compared in terms of pre-, peri-, and post-operative variables. The patients were subdivided into "high-risk" and "low-risk" groups based on the pre-operative catheterisation data. The most frequent main diagnosis was tricuspid atresia (n: 13, 19%). Among 69 patients, 28 (40%) had prolonged pleural effusion whereas 11 (16%) had effusions that lasted longer than 14 days. Ten patients among prolonged effusion group (35%) had pulmonary atresia coexistent with the main diagnosis. Fontan operation was performed in 6 patients (8.7%) over the age of 10, and 4 of these patients (67%) had prolonged pleural effusion. Among numerous variables, statistical significance between the two groups was achieved in pre-operative mean pulmonary artery pressure, post-operative albumin, C-reactive protein levels, length of hospital stay, duration of chest tube drainage, and amount of effusion per day. Early recognition and treatment strategies with routine medical protocol use remain to be the cornerstone for the management of post-operative prolonged pleural effusions after Fontan surgery.


  • Open Access

    Erişkinlerde sık görülen 8. kranial sinir hastalıklarında ve santral işitsel işlemleme bozukluklarında odyolojik bulgular

    by Samet Kılıç, İrem Adalılar, Halime Sümeyra Sevmez, Eser Sendesen, Murat Şahin, Hilal Dinçer D’alessandro, Meral Didem Türkyılmaz

  • Open Access

    Erişkinlerde sık görülen iç kulak hastalıklarında odyolojik bulgular

    by Eser Sendesen, Hasan Çolak, Okan Öz, Sare Yıldırım, Murat Şahin, Samet Kılıç, Hilal Dinçer D’alessandro, Meral Didem Türkyılmaz